OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, OncoCyte currently has a consensus rating of “Hold” and a consensus price target of $4.06.

OncoCyte Stock Performance

NASDAQ OCX opened at $2.92 on Friday. OncoCyte has a one year low of $2.08 and a one year high of $4.34. The company’s 50 day moving average price is $3.07 and its 200 day moving average price is $2.96.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The business had revenue of $0.10 million during the quarter.

Insider Buying and Selling at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the acquisition, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrea S. James acquired 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, with a total value of $99,999.90. Following the acquisition, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. 1.58% of the stock is currently owned by corporate insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.